The Federal 340B Drug Pricing Program has grown from a modest drug discount program into […]
#394 A Tribute to Randy Picker: Revisiting Episode #74 on the Implications of DOJ’s Case Against IBM
We are re-releasing this episode in tribute to Prof. Randy Picker, who passed away on […]
Several U.S. states have recently passed legislation aimed at AI pricing tools that use consumer […]
Competition law isn’t just for antitrust lawyers anymore—it’s increasingly a boardroom issue. What questions should […]
Vertical merger review has long rested on the principle that competitive harm is most likely […]
Recently, the role of lobbying in M&A has become the talk of the antitrust bar […]
In February 2025, new rules for the pre-merger notification requirements in the U.S. came into […]
Over the last few decades, prior approval requirements were considered an extraordinary remedy in merger […]
China’s antitrust regime has evolved rapidly over the past decade. What role does economic analysis […]
Blockchain and cryptocurrency promised to decentralize modern financial markets to take market power away from […]